Cas:24975-73-3 6H-Indeno[4,5-b]furan(8CI) manufacturer & supplier

Chemical Name:6H-Indeno[4,5-b]furan(8CI)

CAS.NO:24975-73-3

Synonyms:6H-Indeno[4,5-b]furan;6H-Indeno[4,5-b]furan(8CI)

Molecular Formula:C₁₁H₈O

Molecular Weight:156.181

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:260.9±9.0 °C at 760 mmHg

Density:1.2±0.1 g/cm3

Index of Refraction:1.672

PSA:13.14000

Exact Mass:156.057510

LogP:3.36

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 6H-Indeno[4,5-b]furan chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6H-Indeno[4,5-b]furan(8CI) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6H-Indeno[4,5-b]furan(8CI) Use and application,6H-Indeno[4,5-b]furan(8CI) technical grade,usp/ep/jp grade.

Related News: Currently allowed as a second-line treatment, Sarclisa is expected to have top-line data from the phase 3 IMROZ trial later this year. The trial is adding Sarclisa to a VRd cocktail of Velcade, Revlimid and dexamethasone, which has established itself as the standard-of-care first-line therapy for patients with myeloma. 6H-Indeno[4,5-b]furan(8CI) manufacturer Genzyme Pharmaceuticals develops and manufactures chemically synthesized pharmaceutical materials and technologies for the global pharmaceutical industry and focuses on lipids, peptides, carbohydrates, oligonucleotides, and custom small molecules. 6H-Indeno[4,5-b]furan(8CI) supplier The company-backed investigation was based on interviews with more than 100 people, the May 20 memo to Lilly employees said. However, the memo did not respond to all concerns employees raised in their April complaint, which Reuters reviewed. 6H-Indeno[4,5-b]furan(8CI) vendor Active Pharmaceutical Ingredients (APIs): Pharmaceutical active ingredients, which are the basic substances that constitute the pharmacological effects of pharmaceuticals, and are prepared by chemical synthesis, plant extraction, or biotechnology. 6H-Indeno[4,5-b]furan(8CI) factory Currently allowed as a second-line treatment, Sarclisa is expected to have top-line data from the phase 3 IMROZ trial later this year. The trial is adding Sarclisa to a VRd cocktail of Velcade, Revlimid and dexamethasone, which has established itself as the standard-of-care first-line therapy for patients with myeloma.